Article3 Biotech2025
AUNIP was a candidate marker for prognosis and immunology in pan-cancer.
Article in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting TROP2 and Exploiting AUNIP as a Determinant of ADC Cytotoxicity and Chemosensitivity in HNSCC and ESCA Cancers.Molecular carcinogenesis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AUNIP (Aurora kinase A[Aurora-A] and ninein-interacting protein), is a key factor regulating the end-state of DNA cleavage. It has been reported that AUNIP affects the progression of some tumors; however, the molecular functions involved in AUNIP remain unknown. We employed some databases, such as TCGA, GTEx, TIMER, GEPIA2, cBioportal, and GSCALite, to study AUNIP gene expression, prognosis, gene variation, and drug sensitivity. The relationship between AUNIP and clinicopathological information was explored using Wilcoxon test. The association between AUNIP and TMB, MSI, immunocyte infiltration, and immune checkpoints were analyzed using Spearman correlation analysis. We employed GSEA to research the functional mechanisms involved in AUNIP for pan-cancer. Moreover, we conducted immunohistochemistry (IHC) to investigate AUNIP difference expression between liver hepatocellular carcinoma (LIHC) and normal tissues. The Chisq test was used to study the correlation of AUNIP with clinical characteristics. AUNIP was highly expressed in majority of tumors and IHC analysis demonstrated that AUNIP expression was higher in LIHC than normal tissues. AUNIP overexpression had adverse outcomes in adrenocortical carcinoma (ACC), brain lower grade glioma (LGG), LIHC, mesothelioma (MESO), and sarcoma (SARC). Furthermore, high AUNIP expression led to unfavorable prognosis in LIHC. AUNIP was associated with T stage, N stage, and clinicopathological analysis in several cancers and AUNIP expression had a correlation with histologic grade in LIHC by IHC. Mutation analysis showed that AUNIP was the highest frequency of genetic changes in cholangiocarcinoma (CHOL). AUNIP was negatively associated with 30 small-molecule drugs that inhibit tumor development. AUNIP expression had association with TMB, MSI, immune cell infiltration, and immune checkpoints for various tumors. GSEA results suggested that AUNIP mainly participated in the cell cycle, DNA replication, mismatch repair, and homologous recombination.Pan-cancer study considered AUNIP as a potential prognostic marker and high latent diagnostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.